The presence of KIT or PDGFRA gain-of-function alterations are highly specific for GIST tumors, found in up to 85% of these tumors, and these alterations also guide treatment decision-making (20–22), with KIT mutations comprising 75%–80% of cases (23–25). The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.